Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 13,082 as of Monday, Nov. 5, 2012, 1:34 PM ET. The NYSE advances/declines ratio sits at 1,351 issues advancing vs. 1,574 declining with 129 unchanged. The Diversified Services industry currently sits up 0.2% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Brink's Company ( BCO), up 9.1%, ExlService Holdings ( EXLS), up 4.7% and Geo Group ( GEO), up 4.5%. On the negative front, top decliners within the industry include Zillow ( Z), down 4.4%, Cintas Corporation ( CTAS), down 1.4%, Mercadolibre ( MELI), down 1.7%, Paychex ( PAYX), down 0.8% and Fidelity National Information Services ( FIS), down 0.9%. TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today: 5. Qiagen ( QGEN) is one of the companies pushing the Diversified Services industry higher today. As of noon trading, Qiagen is up $0.25 (1.4%) to $17.68 on light volume Thus far, 322,781 shares of Qiagen exchanged hands as compared to its average daily volume of 604,500 shares. The stock has ranged in price between $17.34-$17.68 after having opened the day at $17.47 as compared to the previous trading day's close of $17.43. QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. Qiagen has a market cap of $4.2 billion and is part of the services sector. The company has a P/E ratio of 38.6, above the S&P 500 P/E ratio of 17.7. Shares are up 28.5% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Qiagen a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Qiagen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Qiagen Ratings Report now.